https://www.selleckchem.com/products/PLX-4720.html
8% (95% CI, 64.8-90.7%) 68.7% (95% CI, 47.7-89.6%), P = 0.575] and had a significantly higher 3-year LFS than those in the intensified chemotherapy group [77.8% (95% CI, 64.8-90.7%) 28.6% (95% CI, 4.9-52.3%), P = 0.001]. Among the patients who received CAR-T therapy, eight were not bridged to allo-HSCT, and six (75%) remained in remission with a median follow-up of 23.0 months after CAR-T infusion. Our findings show that CAR-T therapy can effectively eliminate MRD and improve survival in patients with a suboptimal MRD response. Our fin